A Milestone in European Cancer Research Collaboration
French biotechnology company Egle Therapeutics has recently secured a substantial €8 million grant from Horizon Europe, the European Union's flagship research and innovation funding program. This funding marks a significant step forward in advancing EGL-001, their lead investigational immunotherapy candidate, into a dedicated neoadjuvant clinical trial for head and neck squamous cell carcinoma (HNSCC). HNSCC, the most common type of head and neck cancer, represents a major health challenge across Europe, where incidence rates continue to rise amid aging populations and persistent risk factors like tobacco use and alcohol consumption.
The grant supports a multicenter, randomized Phase 1/2 trial evaluating EGL-001 in combination with pembrolizumab, a PD-1 inhibitor, in therapy-naïve patients prior to surgery. This neoadjuvant approach—administering treatment before the primary tumor removal—aims to shrink tumors, improve surgical outcomes, and potentially reduce recurrence rates. For researchers and clinicians in higher education institutions, this initiative underscores the vital role of university-led consortia in translating preclinical discoveries into patient benefits.
Introducing Egle Therapeutics: Pioneers in Treg Modulation
Egle Therapeutics, founded in 2020 as a spin-off from the prestigious Institut Curie in Paris, specializes in precision immunotherapies targeting regulatory T cells (Tregs). Tregs are a subset of immune cells that normally prevent overactive responses but can suppress anti-tumor immunity in the tumor microenvironment (TME), contributing to immunotherapy resistance. The company's proprietary platform engineers IL-2 (interleukin-2, a key T-cell growth factor) variants fused to antibodies, enabling selective Treg modulation without broad immune activation that could cause toxicity.
Backed by investors like EQT Life Sciences and Takeda Ventures, Egle has raised over €50 million, including €9.3 million from France 2030 earlier this year. Their pipeline spans oncology and autoimmunity, with EGL-001 leading immuno-oncology efforts. Academic collaborations have been foundational, drawing on decades of Treg research from institutions like Institut Curie.
For those pursuing careers in biotech research, opportunities abound in higher education research positions that bridge academia and industry, much like Egle's origins.
The Science Behind EGL-001: A Dual-Action Treg Starver
EGL-001 is a novel fusion protein combining an antagonist IL-2 mutein with a blocking anti-CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) antibody. Step-by-step, it works as follows: First, the CTLA-4 blocker prevents Tregs from inhibiting effector T cells on antigen-presenting cells. Second, the IL-2 mutein binds selectively to high-affinity IL-2 receptors on Tregs (primarily CD25+), triggering apoptosis (programmed cell death) specifically in the TME. This tumor-selective mechanism minimizes systemic side effects, unlike traditional checkpoint inhibitors.
Preclinical studies presented at the Society for Immunotherapy of Cancer (SITC) 2024 and American Association for Cancer Research (AACR) 2025 demonstrated complete tumor regression in models resistant to PD-1 therapy, with preferential tumor accumulation and rapid clearance from healthy tissues. At ASCO 2025, Egle shared progress from the ongoing Phase 1/2 trial (EGL-121, NCT06622486), showing good tolerability in advanced solid tumors.
Horizon Europe Grant: Forging a Pan-European Consortium
The €8 million award funds a collaborative effort with four elite institutions: University College London (UCL, UK), Vall d’Hebron Institute of Oncology (VHIO, Spain), Gustave Roussy (France), and Technical University of Dresden (TU Dresden, Germany). These partners bring expertise in immunology, genomics, pathology, and computational biology, plus clinical infrastructure across the EU.
- UCL: Leads in translational oncology research.
- VHIO: Headed by early-phase immunotherapy expert Elena Garralda, known for biomarker-driven trials.
- Gustave Roussy: Prof. Aurélien Marabelle's team pioneers IO combinations; site for ongoing EGL-001 trial.
- TU Dresden: Excels in computational biology for patient selection.
This consortium exemplifies Horizon Europe's mission to pool academic strengths for high-impact clinical research. For European higher education professionals, such grants highlight funding avenues for cross-border projects.
Why Focus on Neoadjuvant HNSCC? Addressing a Critical Need
HNSCC arises in the oral cavity, pharynx, larynx, and sinuses, often linked to HPV, smoking, and alcohol. In Europe, GLOBOCAN 2022 estimates underscore its burden: part of ~660,000 new HNC cases regionally, with ~250,000 deaths globally for HNSCC subtypes. Projections indicate rising incidence through 2035 due to demographics.
Standard neoadjuvant therapy (chemoradiotherapy) yields 5-year survival of 40-60% for locally advanced cases, but recurrence is common. Immunotherapies like pembrolizumab (Keytruda®) gained EU approval in 2025 for neoadjuvant/adjuvant use based on KEYNOTE-689 (30% EFS improvement). Yet, Tregs drive resistance in "cold" HNSCC tumors. EGL-001's Treg depletion could synergize, especially pre-surgery when TME is accessible.
Ongoing EGL-001 Phase 1/2 trial detailsCurrent Landscape of HNSCC Immunotherapy in Europe
Europe leads in IO adoption, with the cancer immunotherapy market projected at €36.5 billion in 2025, growing 9.5% CAGR. HNSCC therapeutics market to hit €2.6B by 2032, driven by precision oncology.
Neoadjuvant trials show promise: Meta-analyses report high pathological response rates (up to 50%) with PD-1/CTLA-4 combos. However, only 20-30% achieve major responses, highlighting need for novel agents like Treg starvers. Horizon Europe 2026 calls emphasize cancer missions, aligning with this grant.
Stakeholders, including universities, benefit: Translational data will inform biomarkers for patient stratification.
Preclinical Promise and Early Clinical Signals
In syngeneic mouse models, EGL-001 monotherapy eradicated PD-1-resistant tumors; combos enhanced efficacy. Biodistribution: 10x higher tumor retention vs. periphery. Phase 1 dose escalation (mono/combo) ongoing at Gustave Roussy and VHIO; top-line H2 2026 expected, focusing on safety and RP2D.
- Dose escalation complete in healthy volunteers for related EGL-003.
- No DLTs reported to date in oncology cohort.
- Expansion cohorts planned post-RP2D.
Challenges in Treg-Targeted Therapy and Solutions
Tregs express high CTLA-4/CD25, but systemic depletion risks autoimmunity. EGL-001's design—IL-2 mutein bias + tumor homing—addresses this. Challenges: Biomarker identification (e.g., Treg density via genomics), combo toxicities. Consortium's multi-omics will generate actionable insights.
Real-world case: In HNSCC, high intratumoral Tregs correlate with poor PD-1 response; depletion restores effector function.
Tips for academic CVs in IO research
Implications for European Higher Education and Research Careers
This grant exemplifies EU priorities, fostering university-industry ties. Institutions like UCL and TU Dresden gain funding for trials, training postdocs/clinicians. For aspiring researchers, postdoc positions in immunotherapy are booming.
Future outlook: If successful, EGL-001 could enter Phase 3 by 2028, reshaping neoadjuvant standards. Broader Treg platforms (EGL-002 CCR8-targeted) promise multi-indication impact.
Looking Ahead: Transforming HNSCC Outcomes
The Egle-Horizon consortium positions Europe at the forefront of next-gen IO. With top-line Phase 1 data imminent and neoadjuvant trial launch, EGL-001 offers hope for better survival in HNSCC. Researchers can explore university jobs, higher ed careers, or rate professors in oncology. Stay informed via career advice resources.
Explore research jobs in Europe to join such innovations.